Background/aim: To compare the behavioural and neurobiological consequences of chronic headache and chronic mild stress (CMS) in rats.
Materials And Methods: Forty-eight male Wistar rats were divided into 4 groups: 1) control group, 2) chronic headache group, 3) CMS group, and 4) sham group. Their behaviour prior to (D0) and after (D14) chronic stress was analysed. Afterwards, they were exposed to the Elevated Plus Maze (EPM) in order to evaluate anxiety-like behaviour and the Forced Swim Test (FST) for observation of depressive-like behaviour. Ultrasonic vocalisations (USVs) were recorded by a USV detector system at DO and D14 and during the FST. The c-fos expressions in various brain regions were analysed 2 h after the EPM and FST.
Results: The control group showed significantly more sleeping behaviour at D14 (χ2 = 8.213, P = 0.042), emitted more negative and positive affect USVs at D14 (χ2 = 9.853, P = 0.020) and during FST (χ2 = 4.000, P = 0.046) than the chronic headache and CMS groups, and showed significantly less anxiety-like behaviour in the EPM than the CMS group (P = 0.021).
Conclusion: These results suggest that CMS increases anxiety-like behaviour but not depressive-like behaviour, while chronic headache does not have a significant effect on these behaviours in rats.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3906/sag-1309-24 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Activation of δ-opioid receptors blocks allodynia in a model of headache induced by PACAP.
Br J Pharmacol
January 2025
Center for Clinical Pharmacology, Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Background And Purpose: Pituitary adenylate cyclase activating polypeptide (PACAP) is a human migraine trigger that is being targeted for migraine. The δ-opioid receptor (δ-receptor) is a novel target for the treatment of migraine, but its mechanism remains unclear. The goals of this study were to develop a mouse PACAP-headache model using clinically significant doses of PACAP; determine the effects of δ-receptor activation in this model; and investigate the co-expression of δ-receptors, PACAP and PACAP-PAC1 receptor.
View Article and Find Full Text PDFSerial systemic immune inflammation indices: markers of acute migraine events or indicators of persistent inflammatory status?
J Headache Pain
January 2025
School of Psychology and Public Health, La Trobe University, Melbourne, VIC, 3086, Australia.
Background: Migraine is the most common complex neurological disorder, affecting over a billion people worldwide. Neurogenic inflammation has long been recognized as a key factor in the pathophysiology of migraine though little research has been directed to investigating whether inflammation is greatest in migraine with aura or without, and whether inflammation is a permanent state in migraine or whether is an event related transitory state. Thus, the primary aim of this single-centre, retrospective study was to explore the potential clinical utility of the Serial Systemic Immune-Inflammatory Indices (SSIIi) as a comparative measure of duration and severity of inflammation derived from routine blood cell counts in migraine patients with aura and no-aura both within an acute inpatient setting and as outpatients.
View Article and Find Full Text PDFThe burden of headache disorders among medical students in Vietnam: estimates from a cross-sectional study with a health-care needs assessment.
J Headache Pain
January 2025
Department of Internal Medicine, VNU University of Medicine and Pharmacy, Hanoi, Vietnam.
Background: In our previous study, we demonstrated that headaches are highly prevalent among medical students in Vietnam. In the present study, we provide estimates of the associated symptom burden and impaired participation, utilizing these estimates to assess headache-related healthcare needs within this population.
Methods: The study followed the standardized methodology established by the Global Campaign against Headache.
Characteristics of adverse events and clinical risks of Lecanemab based on FAERS data.
J Affect Disord
January 2025
Affiliated Mental Health Center of Jiangnan University, Wuxi Central Rehabilitation Hospital, Wuxi, Jiangsu 214151, China. Electronic address:
Objective: This study aims to analyze the distribution of adverse events (AEs) related to Lecanemab in real-world settings based on FAERS database data.
Methods: Using the FAERS database, AE data related to Lecanemab was collected from Q3 2023 to Q2 2024. Signal mining was conducted using frequency and Bayesian methods to identify positive signals associated with Lecanemab.
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial.
Lancet Gastroenterol Hepatol
January 2025
Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
Background: Tamuzimod (VTX002) is a selective sphingosine 1-phosphate receptor 1 modulator in development for ulcerative colitis. We aimed to assess the safety and efficacy of tamuzimod in patients with moderately-to-severely active ulcerative colitis.
Methods: This double-blind, randomised, placebo-controlled, phase 2 induction trial was conducted at 122 centres across 15 countries in Asia, Europe, and North America.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!